Gingivitis efficacy of a 0.454% w/w stannous fluoride dentifrice: a 24-week randomized controlled trial

Abstract Background Plaque-induced gingivitis can be prevented and treated with regular effective oral hygiene, principally via mechanical cleaning with regular toothbrushing. To complement the mechanical plaque removal, antimicrobial ingredients can be incorporated into dentifrices to inhibit the g...

Full description

Bibliographic Details
Main Authors: C. R. Parkinson, K. R. Milleman, J. L. Milleman
Format: Article
Language:English
Published: BMC 2020-03-01
Series:BMC Oral Health
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12903-020-01079-6
_version_ 1818578302922653696
author C. R. Parkinson
K. R. Milleman
J. L. Milleman
author_facet C. R. Parkinson
K. R. Milleman
J. L. Milleman
author_sort C. R. Parkinson
collection DOAJ
description Abstract Background Plaque-induced gingivitis can be prevented and treated with regular effective oral hygiene, principally via mechanical cleaning with regular toothbrushing. To complement the mechanical plaque removal, antimicrobial ingredients can be incorporated into dentifrices to inhibit the growth of plaque. This study aimed to evaluate and compare gingivitis and the proportion of subjects moving between gingivitis severity (< 10, > 10 < 30, > 30% bleeding sites), and plaque reduction, following twice daily use of an experimental non-aqueous 0.454% weight/weight (w/w) stannous fluoride (SnF2) dentifrice, compared to a negative control dentifrice over 12 and 24 weeks. Method This was a single-center, examiner-blinded, randomized, stratified, two-treatment arm, parallel group, 24-week clinical study in healthy adult volunteers with moderate gingivitis. At baseline, after abstaining from toothbrushing overnight, subjects underwent MGI (modified gingival index), BI (bleeding index) and PI (plaque index) assessments. Eligible subjects, who met the inclusion/exclusion criteria, were stratified based on gender and baseline mean MGI score (Low ≤2.00 /High > 2.00) and randomized to treatment. Following randomization, subjects underwent a thorough dental prophylaxis and flossing. After 12 and 24 weeks of twice daily brushing with their allocated treatment, subjects returned to the site (with overnight plaque, having abstained from oral hygiene procedures for 8 h prior to visit) for MGI, BI and PI assessments. Treatment effect was evaluated by comparing the MGI, BI and PI scores. Results One hundred and twenty-nine subjects were screened; 98 subjects were randomized and 90 subjects completed the study. Statistically significant differences between treatments, in favour of the 0.454% stannous fluoride dentifrice were observed, compared to the negative control dentifrice, for all outcome measures (MGI, BI, bleeding sites and PI at weeks 12 and 24 p < 0.0001). At 24 weeks, 71% of subjects in the 0.453% SnF2 treatment group demonstrated < 10% of bleeding sites. Conclusion A dentifrice containing 0.454% w/w SnF2 was shown to be superior to a standard dentifrice in controlling gingivitis and supra-gingival plaque, over a 24-week period. Over two thirds of subjects in the 0.454% SnF2 treatment group demonstrated a level of bleeding sites potentially representative of “clinical periodontal health” (< 10%) following a dental prophylaxis and 24 weeks of product use. Trial registration This study was retrospectively registered at ClinicalTrials.gov, on 11th Oct. 2019 ( NCT04123665 ).
first_indexed 2024-12-16T06:43:39Z
format Article
id doaj.art-6020b99e2c4143e2afd764a39b2eafec
institution Directory Open Access Journal
issn 1472-6831
language English
last_indexed 2024-12-16T06:43:39Z
publishDate 2020-03-01
publisher BMC
record_format Article
series BMC Oral Health
spelling doaj.art-6020b99e2c4143e2afd764a39b2eafec2022-12-21T22:40:37ZengBMCBMC Oral Health1472-68312020-03-012011810.1186/s12903-020-01079-6Gingivitis efficacy of a 0.454% w/w stannous fluoride dentifrice: a 24-week randomized controlled trialC. R. Parkinson0K. R. Milleman1J. L. Milleman2GlaxoSmithKline Consumer HealthcareSalus Research, Inc.Salus Research, Inc.Abstract Background Plaque-induced gingivitis can be prevented and treated with regular effective oral hygiene, principally via mechanical cleaning with regular toothbrushing. To complement the mechanical plaque removal, antimicrobial ingredients can be incorporated into dentifrices to inhibit the growth of plaque. This study aimed to evaluate and compare gingivitis and the proportion of subjects moving between gingivitis severity (< 10, > 10 < 30, > 30% bleeding sites), and plaque reduction, following twice daily use of an experimental non-aqueous 0.454% weight/weight (w/w) stannous fluoride (SnF2) dentifrice, compared to a negative control dentifrice over 12 and 24 weeks. Method This was a single-center, examiner-blinded, randomized, stratified, two-treatment arm, parallel group, 24-week clinical study in healthy adult volunteers with moderate gingivitis. At baseline, after abstaining from toothbrushing overnight, subjects underwent MGI (modified gingival index), BI (bleeding index) and PI (plaque index) assessments. Eligible subjects, who met the inclusion/exclusion criteria, were stratified based on gender and baseline mean MGI score (Low ≤2.00 /High > 2.00) and randomized to treatment. Following randomization, subjects underwent a thorough dental prophylaxis and flossing. After 12 and 24 weeks of twice daily brushing with their allocated treatment, subjects returned to the site (with overnight plaque, having abstained from oral hygiene procedures for 8 h prior to visit) for MGI, BI and PI assessments. Treatment effect was evaluated by comparing the MGI, BI and PI scores. Results One hundred and twenty-nine subjects were screened; 98 subjects were randomized and 90 subjects completed the study. Statistically significant differences between treatments, in favour of the 0.454% stannous fluoride dentifrice were observed, compared to the negative control dentifrice, for all outcome measures (MGI, BI, bleeding sites and PI at weeks 12 and 24 p < 0.0001). At 24 weeks, 71% of subjects in the 0.453% SnF2 treatment group demonstrated < 10% of bleeding sites. Conclusion A dentifrice containing 0.454% w/w SnF2 was shown to be superior to a standard dentifrice in controlling gingivitis and supra-gingival plaque, over a 24-week period. Over two thirds of subjects in the 0.454% SnF2 treatment group demonstrated a level of bleeding sites potentially representative of “clinical periodontal health” (< 10%) following a dental prophylaxis and 24 weeks of product use. Trial registration This study was retrospectively registered at ClinicalTrials.gov, on 11th Oct. 2019 ( NCT04123665 ).http://link.springer.com/article/10.1186/s12903-020-01079-6Stannous fluorideDentifriceGingivitisPlaque
spellingShingle C. R. Parkinson
K. R. Milleman
J. L. Milleman
Gingivitis efficacy of a 0.454% w/w stannous fluoride dentifrice: a 24-week randomized controlled trial
BMC Oral Health
Stannous fluoride
Dentifrice
Gingivitis
Plaque
title Gingivitis efficacy of a 0.454% w/w stannous fluoride dentifrice: a 24-week randomized controlled trial
title_full Gingivitis efficacy of a 0.454% w/w stannous fluoride dentifrice: a 24-week randomized controlled trial
title_fullStr Gingivitis efficacy of a 0.454% w/w stannous fluoride dentifrice: a 24-week randomized controlled trial
title_full_unstemmed Gingivitis efficacy of a 0.454% w/w stannous fluoride dentifrice: a 24-week randomized controlled trial
title_short Gingivitis efficacy of a 0.454% w/w stannous fluoride dentifrice: a 24-week randomized controlled trial
title_sort gingivitis efficacy of a 0 454 w w stannous fluoride dentifrice a 24 week randomized controlled trial
topic Stannous fluoride
Dentifrice
Gingivitis
Plaque
url http://link.springer.com/article/10.1186/s12903-020-01079-6
work_keys_str_mv AT crparkinson gingivitisefficacyofa0454wwstannousfluoridedentifricea24weekrandomizedcontrolledtrial
AT krmilleman gingivitisefficacyofa0454wwstannousfluoridedentifricea24weekrandomizedcontrolledtrial
AT jlmilleman gingivitisefficacyofa0454wwstannousfluoridedentifricea24weekrandomizedcontrolledtrial